CSF3 and Decreased total leukocyte count: Fewer adverse events were due to reduced doses of chemotherapy drugs in the mFOLFIRINOX group, and some of the patients who used mFOLFIRINOX were administered granulocyte colony-stimulating factor (GCSF) in advance to prevent leukopenia.